Photo of Richard Geoffrey Vile

View Scopus Profile

Richard Geoffrey Vile, PhD

  • 13106 Citations
  • 66 Scopus h-Index
1989 …2020

Research output per year

If you made any changes in Pure these will be visible here soon.

Fingerprint Dive into the research topics where Richard Geoffrey Vile is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 15 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects

Core A: Administrative Core

Mandrekar, S. J., Torbenson, M., Gores, G. J., Alberts, S. R. & Vile, R. G.

Project: Research project

Enhancing Therapy of Primary and Recurrent Tumors With Systemic Oncolytic Virus

Vile, R. G.

5/7/14 → 4/30/19

Project: Research project

Enhancing Systemic Delivery of Oncolytic Viruses for Cancer Therapy

Vile, R. G.

1/1/09 → 11/30/14

Project: Research project

Autoimmunity and anti tumor immunity outside of the melanocyte/melanoma paradigm

Vile, R. G.

7/1/08 → 5/31/14

Project: Research project

T Cell Based Carriers for In Vivo Gene Therapy of Cancer

Vile, R. G.

4/1/04 → 11/30/14

Project: Research project

Research Output

APOBEC3B-mediated corruption of the tumor cell immunopeptidome induces heteroclitic neoepitopes for cancer immunotherapy

Driscoll, C. B., Schuelke, M. R., Kottke, T., Thompson, J. M., Wongthida, P., Tonne, J. M., Huff, A. L., Miller, A., Shim, K. G., Molan, A., Wetmore, C., Selby, P., Samson, A., Harrington, K., Pandha, H., Melcher, A., Pulido, J. S., Harris, R., Evgin, L. & Vile, R. G., Dec 1 2020, In : Nature communications. 11, 1, 790.

Research output: Contribution to journal › Article

Open Access
    • 1 Scopus citations

    Generation of a Tumor-Specific Chemokine Gradient Using Oncolytic Vesicular Stomatitis Virus Encoding CXCL9

    Eckert, E. C., Nace, R. A., Tonne, J. M., Evgin, L., Vile, R. G. & Russell, S. J., Mar 27 2020, In : Molecular Therapy - Oncolytics. 16, p. 63-74 12 p.

    Research output: Contribution to journal › Article

    Open Access

    • The PERK Inhibitor GSK2606414 Enhances Reovirus Infection in Head and Neck Squamous Cell Carcinoma via an ATF4-Dependent Mechanism

    McLaughlin, M., Pedersen, M., Roulstone, V., Bergerhoff, K. F., Smith, H. G., Whittock, H., Kyula, J. N., Dillon, M. T., Pandha, H. S., Vile, R., Melcher, A. A. & Harrington, K. J., Mar 27 2020, In : Molecular Therapy - Oncolytics. 16, p. 238-249 12 p.

    Research output: Contribution to journal › Article

    Open Access

    • Diverse immunotherapies can effectively treat syngeneic brainstem tumors in the absence of overt toxicity

    Schuelke, M. R., Wongthida, P., Thompson, J., Kottke, T., Driscoll, C. B., Huff, A. L., Shim, K. G., Coffey, M., Pulido, J., Evgin, L. & Vile, R. G., Jul 17 2019, In : Journal for ImmunoTherapy of Cancer. 7, 1, 188.

    Research output: Contribution to journal › Article

    Open Access

    • Phase I trial of an ICAM-1-targeted immunotherapeutic-coxsackievirus A21 (CVA21) as an oncolytic agent against non muscle-invasive bladder cancer

    Annels, N. E., Mansfield, D., Arif, M., Ballesteros-Merino, C., Simpson, G. R., Denyer, M., Sandhu, S. S., Melcher, A. A., Harrington, K. J., Davies, B., Au, G., Grose, M., Bagwan, I., Fox, B., Vile, R., Mostafid, H., Shafren, D. & Pandha, H. S., Jan 1 2019, In : Clinical Cancer Research. 25, 19, p. 5818-5831 14 p.

    Research output: Contribution to journal › Article

    • 10 Scopus citations